Analysis of blood markers for early colorectal cancer diagnosis

dc.contributor.authorBayo Calero, Juan Lucas
dc.contributor.authorCastaño López, Miguel Ángel
dc.contributor.authorCasado Monge, Pedro Germán
dc.contributor.authorDíaz Portillo, Jacobo
dc.contributor.authorBejarano García, Ana
dc.contributor.authorNavarro Roldán, Francisco Juan
dc.date.accessioned2023-06-23T11:23:26Z
dc.date.available2023-06-23T11:23:26Z
dc.date.issued2022
dc.description.abstractBackground: Colorectal cancer (CRC) is a very common tumor worldwide. Its mortality can be limited by early diagnosis through screening programs. These programs are based on fecal occult blood testing and colonoscopy. Our objective was to find a model based on the determination of blood biomarkers that was efficacious enough to become part of the early diagnosis of CRC. Methods: In a total of 221 patients who underwent a colonoscopy, two types of markers were identified (I) classic: carcinoembryonic antigen (CEA), CA19.9, α-fetoprotein, CA125, CA72.4, and ferritin; and (II) experimental: neutrophil gelatinase-associated lipocalin (NGAL), estimated glomerular filtration rate (EGFR), 8-hydroxydeoxyguanosine (8OHdG), calprotectin, and cysteine-rich 61 (Cyr61). We divided the patients into four groups according to colonoscopy results: a control group (n=83) with normal colonoscopy, a polyp group (n=56), a CRC group (n=45), and an inflammatory disease group (n=37). We built an algorithm based on multivariate logistic regression analysis. Results: A total of 51.6% were males, and the median age was 63 years. We designed an algorithm based on the combination of several markers that discriminated CRC patients from the rest of the patients with a performance of 94%, a sensitivity of 95.6%, and a specificity of 80.6%. Discriminating by sex also resulted in two powerful algorithms, although it performed better in males (97% vs. 91%). Conclusions: Our study has devised a predictive model with high efficacy based on the determination of several biomarkers. We think that it could be incorporated into the set of methods used in CRC screening.es_ES
dc.description.departmentCiencias Integradas
dc.description.sponsorshipThe authors are grateful for the technical support of the Research Unit of our hospital (FABIS) and the financial support of the company Bioprognos SL. This manuscript underwent language editing by American Journal Experts. Transcript Profling was done by FABIS (Fundación Andaluza Beturia para la Investigación en Salud, https://www.fabis.org/contacto/). This work was supported by the company Bioprognos SL.es_ES
dc.identifier.citationBayo Calero J, Castaño López MA, Casado Monge PG, Díaz Portillo J, Bejarano García A, Navarro Roldán F. Analysis of blood markers for early colorectal cancer diagnosis. Journal of Gastrointestinal Oncology 2022;13(5):2259-2268. doi: 10.21037/jgo-21-747es_ES
dc.identifier.doi10.21037/jgo-21-747
dc.identifier.issn2078-6891
dc.identifier.issn2219-679X (electrónico)
dc.identifier.urihttps://hdl.handle.net/10272/22237
dc.language.isoenges_ES
dc.publisherAME Publishinges_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subject.otherSerum biomarkerses_ES
dc.subject.otherNoninvasive screeninges_ES
dc.subject.otherEarly detectiones_ES
dc.subject.otherProteomicses_ES
dc.subject.unesco32 Ciencias Médicases_ES
dc.titleAnalysis of blood markers for early colorectal cancer diagnosises_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationd5dc9cac-5ed0-4b20-b710-c818bef27e68
relation.isAuthorOfPublication.latestForDiscoveryd5dc9cac-5ed0-4b20-b710-c818bef27e68

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
68349-PB10-5375-R2.pdf
Size:
651.37 KB
Format:
Adobe Portable Document Format
Description:
Versión editor

Collections